Trial Profile
Neoadjuvant Immune-Modulating Radiation With Durvalumab (MEDI4736) Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma (RADIANT)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms RADIANT
- 21 Mar 2023 Planned number of patients changed from 25 to 16.
- 21 Mar 2023 Planned primary completion date changed from 1 Feb 2022 to 1 Oct 2023.
- 22 Feb 2021 Status changed from not yet recruiting to recruiting.